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Aims Patientswith conditions that are associatedwith insulin resistance such as obesity, type 2 diabetesmellitus, and polycystic
ovary syndrome have an increased risk of thrombosis and a concurrent hyperactive platelet phenotype. Our aim was to
determine whether insulin resistance of megakaryocytes/platelets promotes platelet hyperactivation.
Methods
and results
We generated a conditional mouse model where the insulin receptor (IR) was specifically knocked out in megakaryo-
cytes/platelets and performed ex vivo platelet activation studies inwild-type (WT) and IR-deficient platelets bymeasuring
aggregation, integrinaIIbb3 activation, and dense anda-granule secretion.Deletion of IR resulted in an increase in platelet
count and volume, and blocked the action of insulin on platelet signalling and function. Platelet aggregation, granule se-
cretion, and integrin aIIbb3 activation in response to the glycoprotein VI (GPVI) agonist collagen-related peptide
(CRP) were significantly reduced in platelets lacking IR. This was accompanied by a reduction in the phosphorylation
of effectors downstream of GPVI. Interestingly, loss of IR also resulted in a reduction in insulin-like growth factor-1
(IGF-1)- and insulin-like growth factor-2 (IGF-2)-mediated phosphorylation of IRS-1, Akt, and GSK3b and priming of
CRP-mediated platelet activation. Pharmacological inhibition of IR and the IGF-1 receptor inWT platelets recapitulated
the platelet phenotype of IR-deficient platelets.
Conclusions Deletion of IR (i) increases platelet count and volume, (ii) does not cause platelet hyperactivity, and (iii) reduces GPVI-
mediated platelet function and platelet priming by IGF-1 and IGF-2.
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1. Introduction
Platelets are small anucleate cells that are formed from megakaryocytes,
and their primary function is to regulate haemostasis.1 Platelets normally
circulate in a resting discoid state, maintained by factors released from an
intact endothelium. When a vessel is damaged an underlying matrix of
proteins including collagen are exposed, to which the platelets are able
torapidlyadhere.Thiswill leadtoplatelet activation that includes (i) secre-
tion of mediators from dense and a-granules that can activate and
recruit platelets to the site of injury, (ii) activation of the integrin aIIbb3
which causes platelets to aggregate through bridging interactions with
fibrinogen, and (iii) promotion of coagulation reactions that produce
thrombin to further amplify activation. The resulting primary platelet
plugwill limitblood loss.Dysregulationof theseprocesses leadstoplatelet
hyperactivity promoting aberrant thrombosis. Platelet hyperactivity and a
concurrent increased risk in thrombotic complications areoftenreported
in patientswithobesity, type 2 diabetesmellitus (T2DM), polycystic ovary
syndrome, high blood pressure, and abnormal cholesterol levels.2–4One
of the common factors in these diseases is insulin resistance, a condition
where cells have a reduced ability to respond to insulin.
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Insulin, insulin-like growth factor-1 (IGF-1), and insulin-like growth
factor-2 (IGF-2) are related peptide hormones that mediate their
actions through the structurally similar receptors, including insulin re-
ceptor (IR) and IGF-1-receptor (IGF1R).5–7 These receptors are com-
posed of two monomers comprising an extracellular a-subunit and a
transmembrane b-subunit.8 Ligand binding induces receptor autopho-
sphorylation at various tyrosine residues, recruitment of IR substrates
(IRS), and activation of mitogen-activated protein kinase (MAPK) and
phosphoinositide 3-kinase (PI3K).9 In the case of insulin, which only
has high affinity for IR,10 activation of these signalling pathways pro-
mote downstream processes involved in regulating blood glucose
levels.11 A loss of insulin signalling initially results in increased insulin
production, but eventually leads to hyperglycaemia and development
of T2DM when the body can no longer compensate for the lack of
effect of insulin.
Platelets from insulin-resistant patients show signs of hyperactivity
including (i) reduced responsiveness to the factors released by the
endothelium,12 (ii) increased responsiveness to platelet agonists,13 (iii)
increased levels of the a-granule marker P-selectin (CD62P),14 and
(iv) increased expression of integrinaIIbb3.
15Oneproposedmechanism
for the observed increase in platelet reactivity in insulin-resistant
patients is a reduction in IR signalling. The latter could be through
insulin resistance of megakaryocytes and/or platelets themselves.16–18
A widely accepted approach to study the effect of insulin resistance in
different tissues is the conditional removal of the IR itself,19 which
results in the complete ablation of insulin signalling. This approach has
been instrumental in investigating the pathogenesis of insulin resistance
and diabetes.20–22 Here, we determined whether platelet hyperactivity
in insulin-resistant patients can be attributed to a loss of IR signalling in
megakaryocytes and/or platelets, by investigating platelet function in
platelet/megakaryocyte-specific IR knockout mice (IR KO).
2. Methods
2.1 Mice
Animal studieswere approvedby local research ethics andmice bred for this
purpose under a UKHomeOffice project license (PPL30/2908). To investi-
gate the role of IR expression and function in platelets,mice homozygous for
a floxed IR allele in which loxP sites flank exon 4 of IR gene22 were crossed
with transgenic mice in which expression of Cre recombinase was driven
by the Pf4 gene promoter.23 IRflox/flox Pf4-Cre mice (C57BL/6) were
obtained in a Mendelian ratio and were healthy with no growth abnormal-
ities. IRflox/flox Pf4-Cre+ mice are referred to as KO and age-/sex-matched
IRflox/flox Pf4-Cre2 littermate controls as wild type (WT).
2.2 Reagents
IRS-1, IRS-2, p85, Akt, pSer473 Akt, pGSK3bS9 PKC phospho-motif, pTyr191
linkerof activatedT cells (LAT), pTyr416 Src, pTyr525/526 Syk, pTyr759 PLCg2,
LAT, Syk, PLCg2, and SLP-76 antibodieswere fromCell Signalling Technolo-
gies (New England Biolabs, Hitchin, UK). IR (C-19), IGF1R (C-20), IRS-3
(R-190), and GAPDH antibodies were from Santa Cruz (Insight Biotechnol-
ogy, Wembley, UK). The pTyr128 SLP-76 antibody and Retic-countTM were
from BD Biosciences (Oxford, UK). The anti-phosphotyrosine antibody
4G10 was from Millipore (Watford, UK). FITC-conjugated glycoprotein VI
(GPVI, JAQ1) anti-mouse antibody was from Emfret Analytics (Wurzberg,
Germany). PE-conjugated CD61 (HM beta 3.1) was from AbD Serotec
(Kidlington, UK). Chronolume was from Chrono-log Corporation (Labme-
dics, Manchester, UK). IGF-1 and IGF-2 were from Immunological and
Biochemical Test Systems (Binzwangen, Germany). Cross-linked collagen-
related peptide (CRP-XL) was synthesized by Prof. Richard Farndale
(Department of Biochemistry, University of Cambridge, UK). The PAR-4
agonist (PAR4-activatingpeptide, PAR4-AP, andAYPGKF-NH2)was synthe-
sized by Peptide Synthetics Peptide Protein Research Ltd (Hampshire, UK).
NVP-AEW541 was from Caymen Chemical (Cambridge Bioscience,
Cambridge, UK). IGF-1 mouse/rat quantikine ELISA kit was from R&D
SystemsTM (Abingdon, UK). IGF-2 mouse ELISA kit was from Abcamw
(Cambridge, UK). Microcystin-LR was from Axxora (Nottingham, UK).
Enhanced chemiluminescent detection reagents were from GE Healthcare
(Bucks, UK). Peroxidase-conjugated secondary antibodies were from
Jackson Immunoresearch (Stratech, Newmarket, UK). NuPAGE SDS–
PAGE sample buffer was from Invitrogen (Paisley, UK). All other reagents
were from Sigma (Poole, UK), unless otherwise indicated.
2.3 Platelet isolation
Mice (8–16 weeks old) were sacrificed by rising CO2 inhalation, in
accordance with Schedule 1 of the Animals (Scientific Procedures) Act
(1986), and blood was drawn by cardiac puncture into a syringe containing
4% trisodium citrate (1 : 10, v/v). Femurs were removed for megakaryocyte
quantification experiments. Prior to platelet preparation, complete blood
counts were conducted (Pentra ES60, Horiba) and adjusted for anticoagu-
lant volume. Washed platelets were isolated as previously described.24
Platelets were resuspended at 4 × 108/mL in modified HEPES-Tyrode’s
buffer [145 mmol/L NaCl, 3 mmol/L KCl, 0.5 mmol/L Na2HPO4, 1 mmol/L
MgSO4, 10 mmol/L HEPES, pH 7.2, 0.1% (w/v) D-glucose, 0.02 U/mL
apyrase, and 10 mmol/L indomethacin].
2.4 Megakaryocyte quantification
Murine femurswere immersion-fixed for 1 h in 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer. Both ends of the femur were cut and the marrow
flushed out as awhole piece of tissue by gently flowing through fixative using
a 21-gaugeneedle. Thiswas immersed in freshfixative for a further hour. The
marrow was post-fixed with 1% osmium tetroxide and stained with 1%
uranyl acetate before dehydration through a graded series of ethanol. The
tissue was washed three times with propylene oxide and left rotating over-
night in a 1 : 1 mixture of propylene oxide and Epon. Propylene oxide was
allowed to evaporate over 4 h before the marrow was transferred into
fresh Epon and rotated overnight. The tissue was then mounted in moulds
and left to harden at 608C for 48 h. Thick sections (500 nm) of the entire
length of bone marrow were taken at 20 mm intervals. Sections were
stained with toluidine blue and mounted on coverslips. A stitched tile scan
of the entirebonemarrowareawasacquiredusing anLeicaDMI600 inverted
microscope. Megakaryocytes were positively identified based on size,
morphology, or ploidy and quantified using ImageJ. For TEM imaging, ultra-
thin sections (70 nm) were taken and stained with uranyl acetate followed
by lead citrate. Images were acquired on a Tecnai 12 (FEI).
2.5 Aggregation and ATP secretion
Platelet aggregation and dense granule secretion were monitored as previ-
ously described.25 Briefly, washed platelets (2 × 108/mL) were stimulated
with agonist while simultaneously monitoring aggregation and dense
granule secretion using a luciferin/luciferase reagent (Chronolume) in a
Chronolog 590-2A aggregometer at 378C under stirring conditions.
2.6 Flow cytometry
Two colour analysis of platelet activation was performed as previously
described using a PE-conjugated antibody directed against the high affinity
form of integrin aIIbb3 (JON/A) and a FITC-conjugated antibody for the
a-granule marker CD62P (Wug.E9).25 Platelets (2 × 107/mL) were stimu-
lated with PAR4-AP or CRP-XL in the presence of PE-JON/A and FITC-
CD62P for 10 min. GPVI surface expression was assessed by incubating
resting platelets with a FITC-conjugated GPVI (JAQ1), anti-mouse antibody
for 10 min. All samples were fixed in 1% paraformaldehyde and analysed on
BD LSR II (BD Bioscience) using the FACSDiva software (10 000 platelet
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events per sample). For reticulated platelet quantification, paraformalde-
hyde-fixed blood was diluted 1 : 50 and stained with PE-CD61 antibody
before incubation with thiazole orange solution (Retic-countTM, BD
Biosciences, Oxford, UK) for 1 h. Samples were read on BD LSR II (BD
Bioscience) with platelets identified by their logarithmic side scatter (SSC)
and CD61 positivity expression. The amounts of reticulated platelets are
expressed as the percentage of thiazole orange and CD61-PE double-
positive cells in 10 000 identified platelets.
2.7 Protein extraction, immunoprecipitation
and immunoblotting
Platelets (4 × 108/mL) were incubated with insulin, IGF-1, CRP-XL, or
PAR4-AP as indicated. Platelet suspensions were either lysed directly in
4× NuPAGE sample buffer (whole cell lysate) or extracted with an equal
volume of ice-cold lysis buffer [50 mmol/L Tris pH 7.5, 240 mmol/L NaCl,
2 mmol/L EDTA, 2% (v/v) IGEPAL CA-630, 40 mmol/L sodium b-glycerol
phosphate, 2 mmol/L benzamidine, 2 mmol/L microcystin-LR, 10 mmol/L
sodium orthovanadate, and 2 mg/mL each of pepstatin, antipain, and leupep-
tin] for immunoprecipitation. IRb, p85, IRS-1, and IRS-2 were immunopreci-
pitated from lysates as previously described.24,26 Immunoprecipitates and
whole cell lysates were analysed by SDS–PAGE/western blotting using 6%
Tris-glycine and 8% bis-Tris gels as previously described.24,27 For quantifica-
tion of immunoblotting, densitometry was performed using the ImageJ
software (NIH).
2.8 Quantification of IGF release
IGF-1 and IGF-2 concentrations in platelet releasates were measured using
an IGF-1 mouse/rat quantikine ELISA kit (R&D SystemsTM) or an IGF-2
mouse ELISA kit (Abcamw) following the manufacturer’s protocol. Relea-
sates were prepared by incubating 100 mL of platelets (4 × 108/mL) with
CRP-XL or PAR4-AP as indicated. Platelets were then removed by centrifu-
gation (520 × g, 5 min × 2).
2.9 Statistical analyses
All data are presented as the mean+ S.E.M. of at least three independent
observations. Data presented with statistical analysis were tested using a
Student’s t-test or two-wayANOVAwith Bonferroni post-tests formultiple
comparison analysis. Significance was set as P, 0.05.
3. Results
3.1 Insulin signalling in mouse platelets
We, and others, previously demonstrated that human platelets express
IR, IGF1R, and the substrates IRS-1 and 2.24,26,28 In agreement with these
data, we find that mouse platelets (IRflox/flox Pf4-Cre2) also express IR,
IGF1R, and the substrates IRS-1, 2, and 3 (Figure 1A). Insulin stimulated
rapid tyrosine phosphorylationof IR, phosphorylation of the PI3K effector
Akt at Ser473 (Figure 1B), and tyrosine phosphorylationof IRS-1 and IRS-2,
and their association with the regulatory PI3K subunit p85 (Figure 1C).
Insulin also induced the association of tyrosine-phosphorylated proteins
(160, 100, and 60 kDa) with p85.
3.2 IR-deficient platelets no longer respond
to insulin
Figure 2A demonstrates that we successfully generated a mice line
deficient in platelet IR (IRflox/flox Pf4-Cre+), whereas the levels of key
signalling components such as IGF1R, IRS-1, IRS-2, IRS-3, and Akt
were comparable to WT platelets. Furthermore, IRflox/flox Pf4-Cre+
mice expressed normal levels of IR in liver and skeletal muscle
(Figure 2Aii and iii). Deletion of IR resulted in increased platelet counts
and mean platelet volumes from 785+17 to 845+20 × 03/mL
(P , 0.05, n ¼ 28) and 5.06+0.03 to 5.18+0.04 mm3 (P, 0.05,
n ¼ 28), respectively. This was not accompanied by alterations in the
number or morphology of the megakaryocytes (Figure 2B) or the per-
centage of thiazole orange-positive (reticulated) platelets (Figure 2C).
White and red blood cell counts were not significantly altered.
Insulin (20 nM) significantly increased platelet aggregation induced by
the predominantmurine thrombin receptor PAR-4 inWTmouse plate-
lets (Figure 2D). This correlated with an increase in the activation of the
integrinaIIbb3 byPAR4-AP (Figure2F). Insulin-mediatedenhancementof
integrin activation was observed with insulin concentrations ranging
from 0.5 to 100 nM (data not shown). Loss of the IR resulted in an abla-
tion of the enhancing effect of insulin (Figure 2E and G), demonstrating a
loss of insulin sensitivity. Furthermore, IGF-1, but not insulin, induced
tyrosine phosphorylation of IRS-1 and pSer473 Akt (Figure 2H) in plate-
lets lacking the IR.
3.3 Impaired platelet functional responses
downstream of GPVI in the absence of IR
To investigatewhether insulin resistance affects platelet activity, we ana-
lysed platelet activation by PAR-4 and the collagen receptor GPVI in
IR-deficient platelets. PAR-4-mediated platelet aggregation (Figure 3A)
and dense granule secretion (Figure 3B) were not significantly affected
in IR-deficient platelets. In contrast, CRP-XL-mediated aggregation
and dense granule secretionwere significantly reducedwith an approxi-
mate 50%reduction inATP released in response toCRP-XL at a rangeof
concentrations (Figure 3C andD). Furthermore, we observed analogous
reductions in both CRP-XL-mediated integrin aIIbb3 activation and
a-granule secretion (Figure 3E and F ). This impairment was not due to
a reduction in GPVI levels, as platelet surface expression of GPVI ana-
lysed by FACS was comparable between WT and KO platelets
(1287+40 and 1214+37 mfi, respectively, n ¼ 21).
3.4 Reduction in GPVI-mediated signalling
in IR-deficient platelets
We next investigated whether GPVI-mediated signalling events were
affected in IR-deficient platelets. Stimulation of platelets with CRP-XL
(1 mg/ml) for either 0.5 or 5 min resulted in tyrosine phosphorylation
of FcR g-chain, Syk (Tyr525/6), LAT (Tyr191), SLP-76 (Tyr128), PLCg2
(Tyr759), the PKC substrate pleckstrin, and Akt (Ser473) (Figure 4A–F ).
In comparisonwithWTplatelets, therewas a general decrease in GPVI-
mediated signalling events downstream of GPVI and FcR g-chain phos-
phorylation with significant reductions in Syk (Tyr525/6), SLP-76
(Tyr128), PLCg2 (Tyr759), and pleckstrin phosphorylation (Figure 4A, D,
and E). Surprisingly, although LAT is a substrate of Syk, its phosphoryl-
ation was unaffected. PAR-4 (100 mM, 0.5 and 5 min)-mediated phos-
phorylation of Ser473 Akt and pleckstrin was not significantly altered in
KO platelets (n ¼ 8, data not shown).
3.5 Loss of IR results in a reduction in IGF-1
and IGF-2 signalling
Genetic deletion of IR will result not only in the loss of IR homodimers
but also of IR/IGF1R heterodimers. These IR/IGF1R heterodimers are
thought to play a predominant role in mediating IGF-1s signalling in pla-
telets and support of platelet function.26,29 IR/IGFR heterodimers have a
high affinity for IGF-1, a lower affinity for IGF-2, and low/insignificant af-
finity for insulin.30 IGF-2can furthermoreactivate IR-Ahomodimerrecep-
tors.31 IGF-1 and IGF-2 stimulate association of tyrosine-phosphorylated
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IRS-1 with p85 (Figure 5A) and phosphorylation of Akt (Ser473, Figure 5B)
andGSK3b (Ser9, Figure 5C). IGF-2 inducedweaker phosphorylation than
IGF-1, similar to the results seenwith insulin (Figure 2F). Lossof IR resulted
in a marked reduction in phosphorylation of IRS-1, Akt (Ser473), and
GSK3b (Ser9) induced by both growth factors (Figure 5A–C). These
data suggest that IR homodimers and/or IR/IGF1R hybrids are required
for maximal activation of signalling pathways in platelets by IGF-1 and
IGF-2.
3.6 Impaired GPVI-mediated platelet
function in the presence of IGF-1 and IGF-2
Owing to the decrease in IGF-1/2 signalling, we examined whether the
effect of IGF-1/2 on platelet function was also compromised in
IR-deficient platelets. Stimulation of platelets with PAR4-AP
(Figure 6A–D) or CRP-XL (Figure 6E–H ) in the presence of maximal
concentrations of IGF-1 or IGF-2 resulted in a significant increase in
both PAR-4 and GPVI-mediated integrin aIIbb3 activation (Figure 6A, B,
E, and F ) and a-granule secretion (Figure 6C, D, G, and H ). Increases
induced by either IGF-1 or IGF-2 were comparable. Loss of IR did not
result in significant alterations in platelet activation induced by PAR-4
in the presenceof either IGF-1or IGF-2 (Figure 6A–D). In contrast, integ-
rin aIIbb3 activation and a-granule secretion induced by CRP-XL in
presence of IGF-1 (P, 0.001, n ¼ 3) or IGF-2 (P, 0.001, n ¼ 3)
were significantly reduced in IR-deficient platelets (Figure 6E–H ).
3.7 Pharmacological inhibition of IR/IGF1R
inhibits GPVI-mediated platelet function
Our data suggest that maximal GPVI-mediated platelet activation
requires the tyrosine kinase activity of IR and/or IR/IGF1R. Immunopre-
cipitation of IR demonstrated that IR/IGF1R hybrids are present in
mouse platelets, and that these are tyrosine-phosphorylated by
CRP-XL (Figure 7Ai). Although CRP-XL-induced phosphorylation was
considerably weaker compared with addition of a maximal concentra-
tion of exogenous IGF-1, these data reflect that stimulation of platelets
with CRP-XL can activate IR/IGF1R heterodimers (Figure 7Ai and ii).
To confirm that IR/IGF1R activity is required to support GPVI-
mediated platelet activation, we used NVP-AEW541, a potent inhibitor
of IR and IGF1R kinase activity. Signalling downstream of IGF-1, IGF-2,
and insulin was ablated by NVP-AEW541 (Figure 7B), confirming that
this inhibitor can block IR and IGF1R activity in mouse platelets. Treat-
ment of platelets with NVP-AEW541 resulted in a significant inhibition
of GPVI-mediated integrin aIIbb3 activation and a-granule secretion
(Figure 7C and D) in WT but not in KO platelets. Furthermore, GPVI-
mediated platelet activation in NVP-AEW541-treated WT platelets
Figure 1 Mouse platelets express functional IRs. (A) Immunoblotting demonstrated that IR, IGF1R, IRS-1, and IRS-2 are expressed in human andmouse
platelets. IRS-3 was expressed only in mouse platelets (n ¼ 5). (B) Time course of insulin (20 nM) stimulation of mouse platelets showing tyrosine phos-
phorylation of IR and the PI3K effector Akt (Ser473; n ¼ 3). (C) Insulin (20 nM, 5 min) stimulation of mouse platelets leads to tyrosine phosphorylation of
IRS-1 (i) and IRS-2 (ii) and induces their association with the PI3K regulatory subunit p85 (i– iii) (n ¼ 3). Furthermore, tyrosine-phosphorylated (pY) pro-
teins at 160, 100, and 60 kDa (see arrows)were found to be associatedwith p85 after insulin stimulation (iii). Phosphorylation of the indicated proteinswas
assessed by western blotting of either whole cell lysates or immunoprecipitates (IP). Membranes were reprobed to confirm equal loading.
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Figure 2 Insulin acting at IR enhancesmouse platelet function. (A) Immunoblotting confirmed ablation of IR protein expression in platelets (i) but not in
liver (ii) or skeletal muscle (iii) from IRflox/flox; Pf4-Cre+ (KO) mice. KO platelet expression of IGF1R, IRS-1, 2, 3, and Akt protein were comparable toWT
platelets (i,n ¼ 3). (B) Forevaluationofmegakaryocytenumberandmorphologysectionsof bonemarrowwere imagedwith a transmissionelectronmicro-
scope. The number of megakaryocytes per section was quantified manually using ImageJ, and expressed as the number of megakaryocytes/section cor-
rected for total area of the section. Bars represent means+ SE (n ¼ 3). Data were analysed by Student’s unpaired t-test, and there was no significant
difference in the number of megakaryocytes inWT and KOmice. Subjectively, there was no difference in the subcellular morphology ofWTmegakaryo-
cytes comparedwith those lacking IR. Scale bars ¼ 5 and1 mm. (C ) Forevaluationof reticulatedplatelets byflowcytometry,whole blood fromWTandKO
micewas fixed, stained forCD61-PE, and incubatedwith thiazole orange (Retic-countTM, BDBioscience). Reticulated platelets are expressed as a percent-
ageof thiazole orange andCD61-PE double-positive cells in 10 000 identifiedplatelets. Bars representmean+ SE (n ¼ 3).Datawere analysedby Student’s
unpaired t-test, and there was no significant difference in the number of reticulated platelets inWT and KOmice. (D and E) Monitoring of platelet aggre-
gation using a Chronolog 590-2A aggregometer demonstrated that pre-incubation of platelets (2 × 108/mL) with insulin (20 nM, 5 min) enhances PAR-4-
mediated platelet aggregation inWT (D), but not in IR KO (E) platelets (n ¼ 3). (F andG) In agreement with platelet aggregation, PAR-4-mediated integrin
aIIbb3 activation, as measured by FACS using the JON/A antibody against the high affinity integrin aIIbb3 conformation, was enhanced by insulin (20 nM,
5 min) in WT (F) but not in IR KO platelets (G). FACS results are expressed as mean+ SE of the percentage of maximal fluorescence of vehicle-treated
platelets (n ¼ 13). Data were analysed by two-way ANOVA (P-value), followed by Bonferroni’s post-test (asterisks). A value of P, 0.05 indicates that
insulin significantly altered PAR-4-mediated integrin activation inWT platelets. Asterisks (*P, 0.05, **P, 0.01, and ***P, 0.001) indicate a significant
difference induced by insulin from vehicle at the matching PAR4-AP concentration. (H ) Immunoprecipitation of IRS-1 demonstrates that IGF-1 (100 nM,
5 min), but not insulin (20 nM, 5 min), stimulates tyrosine phosphorylation (pY) of IRS-1 in IR KOplatelets (n ¼ 3). Membraneswere reprobed to confirm
equal loading.
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was not significantly different from IR-deficient platelets in the absence
or presence of NVP-AEW541 (Figure 7C and D). In contrast, PAR-4
(125 mM)-mediated integrin aIIbb3 activation and a-granule secretion
in WT platelets were not significantly reduced by NVP-AEW541
(mfi ¼ 1127+ 223–1192+237 and 292+ 66–315+ 67, respect-
ively, n ¼ 5). Therefore, pharmacological inhibition of IR/IGF1R activity
Figure 3 Deletion of IR results in a reduction in GPVI-mediated platelet activation. (A and B) Monitoring of platelet aggregation and dense granule se-
cretionusing a luciferin/luciferase reagent (Chronolume) in aChronolog590-2Aaggregometerdemonstrated thatPAR4-AP-mediatedplatelet aggregation
(A, n ¼ 11) and dense granule secretion (B, n ¼ 11) were not significantly altered in IR KO platelets. (C and D) In contrast, CRP-XL-mediated platelet ag-
gregation (C, n ¼ 14) and dense granule secretion (D, n ¼ 8) were significantly reduced in IR KO platelets. (E and F ) Furthermore, CRP-XL-mediated in-
tegrinaIIbb3 activation (E, n ¼ 9) anda-granule secretion (F, n ¼ 9)measuredby FACSusing JON/A andCD62P antibodies, respectively,were significantly
reduced in IR KO platelets. Results are expressed as mean+ SE of either the rate of aggregation, ATP nmoles, or mean fluorescence intensity. Data were
analysed by two-way ANOVA (P-value), followed by Bonferroni’s post-test (asterisks). A value of P, 0.05 indicates that CRP-XL-mediated aggregation,
dense and a-granule secretion, and integrin activation were significantly different in IR KO platelets in comparison with WT. Asterisks (*P, 0.05,
**P, 0.01) indicate a significant difference fromWT at the matching CRP-XL concentrations.
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can recapitulate the platelet activation phenotype of IR-deficient
platelets in WT platelets. Taken together, these results conclusively
demonstrate that IR/IGF1R kinase activity is required to support
GPVI-mediated platelet function, and that either deletion of IR or
pharmacological inhibition of IR/IGF1R kinase activity results in impaired
GPVI-mediated platelet function.
Figure 4 Deletion of IR results in a reduction in GPVI signalling. Stimulation of platelets with CRP-XL (1 mg/mL) induced phosphorylation of (A) FcR
g-chain (IP: FcRg-chain, IB:4G10, n ¼ 3), (B) Syk (Tyr525/6, n ¼ 7), (C) LAT (Tyr191, n ¼ 9), (D) SLP-76 (Tyr128, n ¼ 8), (E) PLCg2 (Tyr759, n ¼ 6), (F) pleck-
strin (PKCsubstrates antibody,n ¼ 7), and (G)Akt (Ser473,n ¼ 9). Thedeletionof IR resulted in a significant reduction inSyk, SLP-76, PLCg2, andpleckstrin
phosphorylation (B andD–F). Bars representmeans+ SE of phosphorylation (ratio phosphorylated/total), expressed as a fold change from unstimulated
conditions (CRP-XL, t ¼ 0).Datawere analysedby two-wayANOVA(P-value), followedbyBonferroni’s post-test (asterisks). Avalueof P, 0.05 indicates
thatCRP-XL-mediated Syk, SLP-76, PLCg2, andpleckstrin phosphorylationwere significantly different in IRKOplatelets in comparisonwithWT.Asterisks
(*P, 0.05) indicate a significant difference fromWTat thematching timepoint. Phosphorylationof the indicatedproteinswasassessedbywesternblotting
of either whole cell lysates or immunoprecipitates (IP). Membranes were reprobed to confirm equal loading.
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4. Discussion
We originally hypothesized that megakaryocyte/platelet insulin resist-
ance would result in platelet hyperactivity. Conversely, we found that
platelet activation was unchanged in response to PAR-4 and reduced
in response to GPVI. Several previous studies suggested that insulin re-
sistance ofmegakaryocytes/platelets is the underlying cause of the plate-
let hyperactivity observed in patients with insulin resistance.17,18 Here,
we demonstrate that deletion of IR, using IRflox/flox; Pf4-Cre mice, did
not increase platelet activation in response to either the PAR-4
agonist PAR4-AP or GPVI agonist CRP-XL. Furthermore, whole blood
thrombus formation on collagen was also unaffected (n ¼ 5, data not
shown). The lack of effect is unlikely to be due to species differences
as rodents have been reported to acquire a similar platelet hyperactive
phenotype associated with insulin resistance.32–34 Our results there-
fore demonstrate that the increase in platelet activity observed in con-
ditions/diseases associated with insulin resistance is unlikely to be due
to a loss of megakaryocyte/platelet IR signalling.
Interestingly, IR KO mice had elevated platelet counts and increased
mean platelet volumes, which are frequently reported in patients with
Figure 5 Reduction in IGF-1 and IGF-2 signalling in IR-deficient platelets. Stimulation of platelets (4 × 108/mL) revealed a significant reduction in IGF-1
(100 nM, 5 min) and IGF-2 (100 nM, 5 min) induced phosphorylation of (A) IRS-1 (IP:p85, IB:4G10, and IRS-1, n ¼ 3), (B) Akt [Ser473, n ¼ 13 (IGF-1)/8
(IGF-2)], and (C) GSK3b (Ser9, n ¼ 6). Bars represent means+ SE of phosphorylation (ratio phosphorylated/total), expressed as a fold change from
basal. Data were analysed by Student’s unpaired t-test. Asterisks (*P, 0.05, **P, 0.01) indicate a significant difference from matchedWT stimulation.
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obesity and T2DM,35,36 suggesting that megakaryocyte/platelet insulin
resistance can contribute to the changes in platelet count and volume
in obesity and T2DM. Although it has been suggested that the increase
inmeanplatelet volume inpatientswithT2DM/metabolic syndrome37,38
is due to an increased turnover of the platelet population, we found no
significant alterations in the percentage of circulating reticulated plate-
lets. Furthermore, we observed no significant alterations in megakaryo-
cyte number or morphology, despite a previous study demonstrating
that insulin altered murine megakaryopoiesis in vitro, enhancing the
number of immature megakaryocytes present in cultures.33
Deletion of IR resulted in a significant and specific decrease in GPVI
function in mouse platelets. Furthermore, we found that CRP-XL
induced weak tyrosine phosphorylation of IR/IGF1R heterodimers,
suggesting that these hybrid receptors may play a role in supporting
GPVI-mediated platelet function. One of the mechanisms by which
the tyrosine kinase activity of the IR/IGF1R hybrids could be activated
is by the release of IGFs from activated platelets.39–41 IGF-1 has been
previously demonstrated to amplify platelet activation by autocrine/
paracrine effects through IR/IGFR homodimer and heterodimer recep-
tors.26,29 We also report here for the first time that IGF-2 is able to
enhance platelet function. Deletion of IR will result in a loss of both
IR/IR and IR/IGF1R receptors and may thereby reduce the effect of
IGF-1 and IGF-2 on platelet function. We indeed found a reduction in
IGF1- and IGF2-mediated phosphorylation of IRS-1, Akt, and GSK3 in
IRKOplatelets, suggesting that under normal conditions IGF-1/-2 signal-
ling is predominantly through IR homodimers and IR/IGF1R heterodi-
mers. This was associated with a reduced priming effect of IGF-1 and
IGF-2 on GPVI-mediated platelet function. The reduction in GPVI-
mediated platelet function in IRKOmay therefore be due to impairment
in the effect of released IGFs on platelet function. In support of this, we
found that inhibition of IR and IGFR activity using NVP-AEW541
reduced GPVI-mediated platelet function in WT platelets to the same
extent as IR deletion, but had no effect on IR KO platelets.
Interestingly, however, PAR4-AP-mediated platelet function was
not affected by IR deletion or the IR/IGFR kinase inhibitor NVP-
AEW541, and we were unable to detect IR/IGFR hybrid phosphoryl-
ation by PAR4-AP, demonstrating that IR/IGFR activity and/or released
IGF does not contribute to PAR4-mediated platelet function under
these conditions.
One possible explanation is that CRP-XL is more potent at releas-
ing IGF1/2 than PAR4-AP. We indeed found that CRP-XL (5 mg/mL,
5 min) induced more release of IGF-1 and IGF-2 (44.3+7.25 and
143.3+ 62.2 pM, respectively, increase from basal per 5 × 107 plate-
lets,n ¼ 4) thanPAR4-AP (26.0+0.9 and83.0+ 48.85 pM, respective-
ly, increase from basal per 5 × 107 platelets, n ¼ 3). Although the
concentrations are lower than used in vitro, endogenous IGF1/2 from
the a-granules is released near the membrane and is therefore likely
to be more efficient. Potentially PAR-4 function/signalling pathways
are less reliant on IGF signalling than GPVI pathways, with the threshold
for maximal PAR4-mediated activation still being achieved in the IR KO
mice. Note thatwewere unable to use receptor and/or IGF1/2 blocking
antibodies to confirm a role for released IGF1/2, as control studies
showed that they did not block the effect of IGF1/2 onmurine platelets.
We can therefore not completely exclude the possibility that CRP acti-
vates IR/IGFR hybrid receptors through an alternative mechanism, for
example through ligand-independent trans-phosphorylation/activation
of IR/IGF1R heterodimers.42
The observation that insulin significantly enhanced mouse platelet
activation is interesting, as it demonstrates that signalling downstream
Figure 6 Reduction in CRP-XL, but not in PAR-4 platelet activation,
in the presence of IGF-1 and IGF-2. IGF-1 (n ¼ 6) and IGF-2 (n ¼ 4)
enhanced PAR-4-mediated integrin aIIbb3 activation (A and B) and
a-granule secretion (C and D) to a similar degree in IR KO compared
with WT. In contrast, CRP-XL in the presence of IGF-1 (n ¼ 3) or
IGF-2 (n ¼ 3) failed to induce similar levels of integrin aIIbb3 activation
(E and F) or a-granule secretion (G and H ) in KO platelets compared
withWT. IntegrinaIIbb3 activation anda-granule secretion weremea-
sured by FACS using the JON/A and CD62P antibodies, respectively.
Results are expressed as mean+ SE of the percentage of maximal
fluorescence of vehicle-treated WT platelets. Data were analysed by
two-way ANOVA, followed by Bonferroni’s post-test.
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Figure 7 Pharmacological inhibition of IR/IGF1R reduces GPVI platelet activation to levels comparable to IR-deficient platelets. (A, i) Immunoprecipita-
tionof IR fromplatelet lysates followedby immunoblottingwith4G10 (pY), IR, and IGF1Rantibodiesdemonstrated that IGF-1 (100 nM,5 min) andCRP-XL
(5 mg/ml, 5 min) can induce tyrosine phosphorylation of IR/IGF1R heterodimers (n ¼ 4). Bars (ii) representmeans+ SE of doublet phosphorylation (ratio
phosphorylated/IR total). (B) Immunoblotting demonstrated that pre-incubation of plateletswithNVP-AEW541 (1 mM, 10 min) blocked IGF-1 (i, 100 nM,
5 min), IGF-2 (ii, 100 nM, 5 min), and insulin (iii, 20 nM, 5 min) induced phosphorylation of Akt (Ser473, Thr308) andGSK3b (Ser9) (n ¼ 6, 4, and 3, respect-
ively). Pre-incubation of platelets with NVP-AEW541 (1 mM, 10 min) resulted in a significant reduction inWT, but not in KO CRP-XL-mediated integrin
aIIbb3 activation (C) and a-granule secretion (D) measured by FACS using the JON/A and CD62P antibodies, respectively. Results are expressed as
mean+ SEof the percentageof PAR-4 response (125 mM) (n ¼ 5).Datawere analysedby two-wayANOVA, followedbyBonferroni’s post-test.Asterisks
(*P, 0.05, **P, 0.01, ***P, 0.001) indicate a significant difference fromWT + DMSO at the matching concentration.
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of IR homodimers increases platelet function. We previously reported
that, in human platelets, insulin hadminimal effects on platelet functional
responses,24 as the majority of IR subunits are expressed as IR/IGF1R
heterodimers, which are relatively unresponsive to insulin.26,43 In
contrast, insulin significantly enhanced mouse platelet activation and
stimulated strong phosphorylation of IR homodimers, phosphorylation
of IRS-1 and IRS-2, and activation of PI3K, demonstrating that activation
of IR homodimers increases platelet function.
Taken together, our data demonstrate that megakaryocyte/platelet
insulin resistance may contribute to increases in platelet number and
volume, but not in platelet hyperactivity, in insulin-resistant patients.
Furthermore, insulin, IGF-1 and IGF-2 are able to enhance mouse
platelet activation and a loss in IR/IGF1R activity impacts on GPVI-
mediated signalling and function in platelets.
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